JAK1 and urinary bladder cancer: Somatic mutations in JAK1 have been identified in multiple tumor types including high-risk bladder cancer, endometrial, colorectal, stomach, and prostate carcinomas (17–19) supporting the idea that alterations in JAK1 signaling, whether through loss or gain of function, could play a role in the pathogenesis of some epithelial cancers.